A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2018
Price : $35 *
At a glance
- Drugs LIV-GAMMA SN-SK-plasma (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors SK Plasma
- 18 Apr 2018 Planned End Date changed from 30 Sep 2017 to 30 Aug 2018.
- 18 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 29 May 2017 New trial record